Epilepsy Treatment Devices Market

The global Epilepsy Treatment Devices Market is valued at USD 631.2 Million in 2024 and is projected to reach a value of USD 983.4 Million by 2035 at a CAGR (Compound Annual Growth Rate) of 4.1% between 2025 and 2035. The global market growth is fuelled by technological advancements in neurostimulation devices and growing demand for minimally invasive procedures.

Key Highlights

• Europe dominated the market in 2024, with 30.5% market share due to its high prevalence of epilepsy, advanced healthcare infrastructure, increased awareness and support for innovative and effective treatments
• The Conventional Devices segment held a significant share of the market in 2024 with 48.3% of market share, due to their established effectiveness, widespread adoption, and reliable performance in managing epilepsy
• Based on Application, the Hospitals segment dominated the market in 2024, with 58.2% of the market share, driven by their comprehensive diagnostic capabilities, specialized care for complex cases
• Adoption of the AI-driven technologies for improved device programming,

  seizure

  prediction, and personalized treatment plans boosts the market growth

Product Type Overview

Based on Product Type, the global market is segmented into Wearable Devices, Conventional Devices, Implantable Devices, and Others. The Conventional Devices segment held the largest revenue share of 48.3% of the global market in 2024.

The conventional devices segment holds substantial market share due to its proven safety and effectiveness in epilepsy monitoring. These devices, particularly electroencephalogram (EEG) systems, are crucial for the continuous monitoring of patients. The COVID-19 pandemic further highlighted the importance of these devices, as the demand for epilepsy monitoring increased amid a rise in seizure cases among infected individuals. For example, a study published in June 2021, titled "Epilepsy during the COVID-19 Pandemic Lockdown: A US Population Survey," revealed that 25% of individuals in the United States reported an increase in seizures during the pandemic. This surge in cases drove the adoption of conventional monitoring devices, given their reliability and widespread acceptance among patients.

Conventional devices are also a staple in hospitals & clinics, where they are extensively used for continuous, non-invasive monitoring to assist healthcare professionals in accurately diagnosing the type of seizures and determining appropriate treatments. The growing need for precise, ongoing monitoring of epilepsy has fueled demand for these devices. The introduction of advanced products like iMediSyncs comprehensive EEG solution, iSyncWave, which offers rapid brain health screening & predictive analysis, further contributes to the segments growth.

Regional Overview

In 2024, Europe dominated the global market with a revenue share of 30.5%. Around 15 million Europeans are projected to experience at least one seizure in their lifetime, with an estimated 6 million currently living with epilepsy. The pandemic has exacerbated psychological distress among epilepsy patients in the UK, leading to more severe seizures. Additionally, many young people with epilepsy face emotional and behavioral challenges. As these pre-existing behavioral and mental health issues worsen, it is anticipated to drive revenue growth in the regional market.

Europes significant share of the market is strengthened by the presence of major manufacturers and supportive government initiatives aimed at enhancing healthcare. The rising adoption of telemedicine for epilepsy management further strengthens the market in the region. The growing focus on personalized, patient-centered care and the increasing demand for home-based monitoring solutions are key drivers of the market growth. The regions shift towards value-based care is expected to further boost the utilization of Epilepsy Treatment Devices.

Asia Pacific is projected to be the fastest growing market during the forecast period. This is due to the rising prevalence of epilepsy, increasing healthcare expenditure, and increased awareness of the condition. The emphasis on patient-centric care and the expanding demand for home-based monitoring solutions are contributing to the markets expansion. As the region transitions towards value-based care, the usage of Epilepsy Treatment Devices is expected to rise even further.

Key Trends

1. Advancements in Responsive Neurostimulation (RNS) Systems: Development and integration of closed-loop systems that provide real-time seizure detection and precise therapy delivery.
2. Growth in Vagus Nerve Stimulation (VNS) Therapy: Increasing use of implantable pulse generators with advanced features to enhance VNS Therapy for drug-resistant epilepsy.
3. Expansion of Non-Invasive and Minimally Invasive Therapies: Rise in the use of non-surgical treatments such as transcranial magnetic stimulation (TMS) and other non-invasive methods.
4. Personalization of Treatment Approaches: Growing focus on tailored treatment strategies using patient-specific data and 3D visualization tools to optimize therapy.
5. Increased Investment in Research and Development: Ongoing investment in R&D to innovate and improve Epilepsy Treatment Devices, including new device prototypes and therapeutic approaches.
6. Enhanced Patient Monitoring and Data Collection: Utilization of advanced monitoring systems and wearable technologies to gather comprehensive data on seizure activity and treatment efficacy.
7. Expansion of Global Market Reach: Growing market presence in emerging regions and increased accessibility of advanced treatment devices worldwide.

Market Dynamics

Innovative Treatments and Technologies Provide New Hope for Epilepsy Management

Epilepsy is a challenging condition, with at least 30% of patients not responding to traditional seizure medications. While some individuals can undergo brain surgery to remove the seizure focus, this option only cures epilepsy in about 60% of cases. For those who don't benefit from surgery, alternative treatments like Vagus Nerve Stimulation (VNS) Therapy, dietary interventions such as the ketogenic diet, and the innovative Responsive Neurostimulation (RNS®) Therapy offer hope. Approved by the US Food and Drug Administration (FDA) in 2013, the RNS® System represents a significant advancement in personalized epilepsy treatment. The RNS® System is a sophisticated, adjustable, and reversible device designed to cater to the unique needs of each patient. It continuously monitors brain waves at the seizure focus, detects abnormal electrical activity that may lead to a seizure, and responds with small bursts of stimulation to normalize brain activity before a seizure can occur. This smart technology is similar to a heart pacemaker but is tailored for the brain, aiming to prevent seizures from escalating.

Although the RNS® System is not a cure for epilepsy, it has proven effective in significantly reducing seizures for most users. A real-world study following 130 patients for an average of 2.3 years showed a 67% reduction in seizures after one year, increasing to 82% after three years of use. Additionally, approximately 77% of patients experienced at least a 50% reduction in seizures after two years.

Rising Global Epilepsy Prevalence Fuels Growth in Treatment Device Market

The rising prevalence of epilepsy worldwide is anticipated to fuel the growth of the Epilepsy Treatment Devices market. As per the World Health Organizations update in February 2022, approximately 50 million people globally suffer from epilepsy, making it one of the most widespread neurological conditions. Moreover, nearly 80% of those affected reside in low- and middle-income countries. The WHO also estimates that up to 70% of people with epilepsy could achieve a seizure-free life with proper diagnosis and treatment. Consequently, the growing number of epilepsy cases is expected to boost the demand for Epilepsy Treatment Devices, which are essential for providing critical insights into seizure types. Additionally, the increasing elderly population, who are more susceptible to developing epilepsy and seizures, is another key factor contributing to the markets expansion.

Strategic Investments and Technological Advancements Accelerate Growth

The investments by market players and technological advancements are significantly driving market growth. For example, in July 2022, Breakthrough Victoria invested in the Victorian medical technology company Seer Medical to help it become a global leader in home-based epilepsy monitoring and management. This investment will enable Seer to almost double its workforce and presence in Victoria, as well as expand into the United States and the United Kingdom.

Track market trends LIVE & outsmart rivals with our Premium Data Intel Tool: Vantage Point

Competitive Landscape

Major companies engage in the market through various approaches, including the product innovation, mergers & acquisitions, and strategic partnerships. New entrants into the Epilepsy Treatment Devices market are emphasizing innovation and development.

For instance, in April 2022, Boston Scientific Corporation announced that it has received approval from the US Food and Drug Administration (FDA) for its image-guided programming software, Vercise™ Neural Navigator with STIMVIEW XT. Developed in partnership with Brainlab AG, a prominent software-driven medical technology firm, STIMVIEW XT allows clinicians to visualize lead placement and stimulation modeling of the brain in real-time for patients with Parkinson’s disease or essential tremor. When used with the Vercise Genus Deep Brain Stimulation (DBS) portfolio, STIMVIEW XT provides the most advanced and integrated visualization software for DBS programming. It offers patient-specific 3D anatomical visualization, enabling clinicians to better tailor therapy to each individual’s needs.

Recent Market Developments

Medtronic Receives FDA Approval for Percept RC DBS System

• In January 2024, Medtronic plc, a leading healthcare technology company, has received approval from the US Food and Drug Administration (FDA) for its Percept RC Deep Brain Stimulation (DBS) system. This rechargeable neurostimulator is the latest addition to the Medtronic Percept family, which also includes the Percept PC neurostimulator, BrainSens technology, and SenSight directional leads. The Percept family stands out as the only DBS system on the market with sensing capabilities, enabling physicians to tailor treatment for patients with movement disorders such as Parkinsons disease, essential tremor, dystonia, and epilepsy. In the US, over 11 million people live with movement disorders, and approximately 3.4 million have epilepsy.

LivaNova Launches SenTiva DUO with Dual-Pin Header for Enhanced VNS Therapy

• In February 2023, LivaNova PLC, a leading company in medical technology and innovation, has introduced the SenTiva DUO, an implantable pulse generator (IPG) designed with a dual-pin header for delivering VNS Therapy in the treatment of drug-resistant epilepsy. This new dual-pin header differentiates the SenTiva DUO from the original SenTiva, which features only a single-pin format. With the SenTiva DUO, patients who were among the early adopters of VNS Therapy and initially implanted with a dual-pin lead and IPG can now benefit from the latest advancements in VNS Therapy technology.

NeuroPace Initiates NAUTILUS Study for RNS System in Drug-Resistant Epilepsy

• In October 2022, NeuroPace, Inc., a medical device company dedicated to improving the lives of people with epilepsy, has announced that the first patient has been implanted in the NAUTILUS clinical study. This critical study aims to assess the safety and efficacy of the RNS System for individuals aged 12 and older who have drug-resistant idiopathic generalized epilepsy (IGE), also referred to as primary generalized epilepsy.

The global Epilepsy Treatment Devices market can be categorized as Product Type, Technology, End Users, Application, and Region.